Related Experiment Video
Updated: Dec 11, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Moving Beyond BRCA-Incorporating Molecular Assays into Ovarian Cancer Trials
Michelle McMullen1, Katherine Karakasis1, Amit M Oza2,3
1Princess Margaret Cancer Centre, University Health Network. Toronto, Ontario, Canada.
Abstract:
PrOTYPE is a locked down assay validated to Institute of Medicine standards, using NanoString technology to classify high-grade serous ovarian cancer into four defined subgroups. Future directions will include prospective-retrospective analysis and prospective clinical validation to define the predictive role of this assay and its role in influencing treatment decisions.See related article by Talhouk et al., p. 5411.
More Related Videos
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
04:07Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023